Here's Why Galapagos Stock Rose 20.5% in October
The company reported third-quarter 2019 operating results and deepened its relationship with Gilead Sciences.
Galapagos
GLPG
GLPG
$214.68
-$0.32
-0.1%
BATS BZX Real Time Price as of December 12, 2019, 2:03 p.m. EST
View Interactive GLPG Charts
GALAPAGOS NV SPON ADR REPR 1 ORD SHS
News & Analysis: Galapagos
These 3 European Biotechs Can Help Recession-Proof Your Portfolio
Biotechs trade on the prospects of new advancements to identify and treat diseases. That's something the world needs in good times and bad.
Galapagos NV (GLPG) Q3 2019 Earnings Call Transcript
GLPG earnings call for the period ending September 30, 2019.
Better Buy: Vertex Pharmaceuticals vs. Galapagos
Which stock wins in a matchup between these two successful biotechs?
Here's Why Galapagos NV Rose 34.5% in July
The Belgian biopharma bagged $5.1 billion from its most important partner.
Galapagos NV (GLPG) Q2 2019 Earnings Call Transcript
GLPG earnings call for the period ending June 30, 2019.
Gilead's Galapagos Deal: What It Means for Investors
Here's what Gilead's getting with its $5.1 billion Galapagos collaboration.
3 Soaring Biotech Stocks With More Fuel in the Tank
Despite already massive gains this year, shares of these drugmakers could keep on climbing.
What Happened in the Stock Market Today
From failed takeover talks to a massive new partnership, see why these stocks were on the move on a quiet day for the broader markets.
Why Galapagos NV Stock Is Soaring Today
Gilead Sciences decided to inject $5.1 billion into its R&D partner Galapagos NV over the weekend.
